Entropy Technologies LP Grows Position in Enovis Co. (NYSE:ENOV)

Entropy Technologies LP grew its holdings in shares of Enovis Co. (NYSE:ENOV) by 8.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,305 shares of the company’s stock after purchasing an additional 598 shares during the quarter. Entropy Technologies LP’s holdings in Enovis were worth $321,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. UMB Bank n.a. grew its stake in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the period. Pinnacle Bancorp Inc. grew its stake in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of Enovis during the 3rd quarter worth $55,000. FMR LLC grew its stake in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after acquiring an additional 484 shares during the period. Finally, Heritage Family Offices LLP bought a new position in shares of Enovis during the 3rd quarter worth $206,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Down 0.4 %

Shares of NYSE ENOV opened at $43.70 on Friday. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The business has a 50-day simple moving average of $45.53 and a two-hundred day simple moving average of $44.43. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.48 billion, a P/E ratio of -19.96 and a beta of 1.94.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and set a $65.00 price target on shares of Enovis in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Enovis has an average rating of “Moderate Buy” and an average price target of $64.83.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.